The Amputation Surgical Site Infection Trial (ASSIT)

Sponsor

Hull University Teaching Hospitals NHS Trust (Other)

Overall Status

Completed

CT.gov ID

NCT02018094

Collaborator

University of Hull (Other)

160

Enrollment

Location

Arms

38.8

Actual Duration (Months)

4.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Lower limb amputations are performed usually as a last resort in patients with acute and chronic limb ischaemia (CLI) caused by vascular disease, poorly controlled diabetes or, infection.
In the period 2003-2008 there were approximately 5,000 amputations per year in the UK.
The Centre for Disease Control defines a Surgical Site Infection (SSI) as an infection within 30 days of an operation or up to one year if an implant is left in place and the infection is related to an operative procedure.
Figures from the Surgical Site Infection Surveillance reported that the highest rate of surgical site infection was reported in association with lower limb amputation at 13.1%.
There is a clear under-representation and the infection rate within our institution is approximately 25% which reflects the infection rate reported in a recent trial by Sadat et al (22.5%)
Prevention of surgical site infections is of paramount importance to patients, healthcare providers and policy-makers, as they impact on morbidity and mortality and have significant time and cost implications.
Currently there is NO CONSENSUS as to what the best practice is towards antibiotic administration in such patients. From a questionnaire-based audit we performed including vascular departments across the entire country, practice varies in both course duration (single dose → 5 days antibiotic course) as well as choice of antibiotics.
The guideline at our institution suggests the 5-day course of antibiotic prophylaxis. The course duration varies depending on the clinical picture as well as microbiology results and recommendations.
There are no randomised control trials that have investigated this aspect of patient care. We have set up one such trial and through it, we are looking to establish a standard practice which will hopefully be as beneficial as possible to the patient but also cost-effective for NHS.

Condition or Disease	Intervention/Treatment	Phase
Wound Infection Amputation Wound	Drug: Co-amoxiclav Drug: Iodine Drug: Metronidazole Drug: Chlorhexidine Drug: Teicoplanin Drug: Clindamycin	Phase 4

Detailed Description

As above

Study Design

Study Type:

Interventional

Actual Enrollment :

160 participants

Allocation:

Randomized

Intervention Model:

Single Group Assignment

Masking:

Double (Participant, Investigator)

Primary Purpose:

Treatment

Official Title:

A Randomised Control Trial to Determine Whether a 5 Day Course of Antibiotics is More Clinically and Cost Effective Than a 24 Hour Prophylactic Course for the Prevention of Surgical Site Infection Following Lower Limb Amputation

Actual Study Start Date :

Oct 8, 2013

Actual Primary Completion Date :

Mar 1, 2014

Actual Study Completion Date :

Jan 2, 2017

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: 24 hour antibiotic course 24 hours of the stated antibiotics administered intravenously (Augmentin and metronidazole. Teicoplanin and or gentamicin will be used if penicillin allergic and state of renal function)	Drug: Co-amoxiclav Augmentin 1.2g IV three times daily for 24 hours. If the patient is randomised to the 5-day duration antibiotic arm then Augmentin 625mg oral tablets three times daily are added to the 24 hour course for a further 4 days. Other Names: Augmentin Drug: Iodine Intra-operative skin preparation prior to incision to skin. Other Names: Povidone iodine (alcoholic solution) Drug: Metronidazole 500mg IV three times daily for 24 hours. If the patient is randomised to 5-day duration arm, then another 4 days of oral metronidazole at 400mg three times daily is added to the course Other Names: Flagyl Drug: Chlorhexidine Alcoholic Chlorhexidine skin pre-op preparation Other Names: Hydrex Drug: Teicoplanin Teicoplanin 400mg on induction. If penicillin allergic and on 5-day antibiotic arm then add clindamycin 300mg 4 times daily for further 4 days
Active Comparator: 5 day antibiotic Course 24 hours of IV antibiotics followed by 4 days of oral antibiotics (Augmentin and metronidazole. Teicoplanin and or gentamicin will be used if penicillin allergic and state of renal function. Clindamycin will be used as a an oral replacement for penicillin allergic patients)	Drug: Co-amoxiclav Augmentin 1.2g IV three times daily for 24 hours. If the patient is randomised to the 5-day duration antibiotic arm then Augmentin 625mg oral tablets three times daily are added to the 24 hour course for a further 4 days. Other Names: Augmentin Drug: Iodine Intra-operative skin preparation prior to incision to skin. Other Names: Povidone iodine (alcoholic solution) Drug: Metronidazole 500mg IV three times daily for 24 hours. If the patient is randomised to 5-day duration arm, then another 4 days of oral metronidazole at 400mg three times daily is added to the course Other Names: Flagyl Drug: Chlorhexidine Alcoholic Chlorhexidine skin pre-op preparation Other Names: Hydrex Drug: Teicoplanin Teicoplanin 400mg on induction. If penicillin allergic and on 5-day antibiotic arm then add clindamycin 300mg 4 times daily for further 4 days Drug: Clindamycin Clindamycin 300mg 4 times daily orally to be used in case of penicillin allergy
Active Comparator: Iodine Skin Preparation used pre-operatively: Alcoholic Povidone	Drug: Co-amoxiclav Augmentin 1.2g IV three times daily for 24 hours. If the patient is randomised to the 5-day duration antibiotic arm then Augmentin 625mg oral tablets three times daily are added to the 24 hour course for a further 4 days. Other Names: Augmentin Drug: Iodine Intra-operative skin preparation prior to incision to skin. Other Names: Povidone iodine (alcoholic solution) Drug: Metronidazole 500mg IV three times daily for 24 hours. If the patient is randomised to 5-day duration arm, then another 4 days of oral metronidazole at 400mg three times daily is added to the course Other Names: Flagyl Drug: Teicoplanin Teicoplanin 400mg on induction. If penicillin allergic and on 5-day antibiotic arm then add clindamycin 300mg 4 times daily for further 4 days Drug: Clindamycin Clindamycin 300mg 4 times daily orally to be used in case of penicillin allergy
Active Comparator: Chlorhexidine Skin preparation to be used preoperatively: Alcoholic chlorhexidine	Drug: Co-amoxiclav Augmentin 1.2g IV three times daily for 24 hours. If the patient is randomised to the 5-day duration antibiotic arm then Augmentin 625mg oral tablets three times daily are added to the 24 hour course for a further 4 days. Other Names: Augmentin Drug: Metronidazole 500mg IV three times daily for 24 hours. If the patient is randomised to 5-day duration arm, then another 4 days of oral metronidazole at 400mg three times daily is added to the course Other Names: Flagyl Drug: Chlorhexidine Alcoholic Chlorhexidine skin pre-op preparation Other Names: Hydrex Drug: Teicoplanin Teicoplanin 400mg on induction. If penicillin allergic and on 5-day antibiotic arm then add clindamycin 300mg 4 times daily for further 4 days Drug: Clindamycin Clindamycin 300mg 4 times daily orally to be used in case of penicillin allergy

Outcome Measures

Primary Outcome Measures

Surgical Site Infection [30 days]
Primary objective: to establish the effect of 5 days of antibiotics versus a 24-hour prophylactic course on the incidence of surgical site infection (SSI) - total ASEPSIS score >21

Secondary Outcome Measures

Impact of different skin preparations on infection rates [30 days]
ASEPSIS Questionnaire score >21
Rate of re-intervention [30 days]
Types of re-intervention: angioplasty, bypass, debridement, revision to higher level amputation.
Mortality [1 year]
Mortality of a patient
Satisfactory healing rates [3 months]
Metric Measurement. Asepsis score derived by HPA post-discharge questionnaire. Clinical examination, quality of life, time to prosthesis also recorded.
Quality of life Questionnaire [1 year]
Assessed with Short form (SF)-12 questionnaire
Resource use [up to 3 months]
length of stay, return to surgery, number of visits to general practitioners, hospital visits, and prescription of antibiotics.
Rate of C. Diff., MSSA (Methicillin Sensitive Staphylococcus Aureus), MRSA (Methicillin Resistant Staphylococcus Aureus) infection [30 days]
Infection progress
Mobility [1 year]
Locomotor Capabilities index - 5
Pain Control [1 year]
McGill Pain questionnaire

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Adults ≥18 yrs undergoing lower limb amputations who are able to consent to the trial.
Able to understand the Patient Information Sheet and capable and willing to give informed consent and follow the protocol requirements (including attending all follow-up visits)

Exclusion Criteria:

Allergies to chlorhexidine/ alcohol/ iodophors
Inability to give informed consent
Patients who are admitted to hospital with severe sepsis secondary to gas gangrene requiring multiple operations and admission to Intensive Care Unit.
Aged under 18 years at the time of recruitment
Use of investigational drug/device therapy within preceding 4 weeks that may interfere with this study.
Toe amputations